neonat
high
risk
influenza
morbid
mortal
due
immun
immatur
lack
prime
prior
influenza
viru
exposur
inactiv
influenza
vaccin
ineffect
infant
six
month
provid
protect
older
children
gener
requir
two
dose
given
month
apart
leav
option
rapid
protect
infant
eg
influenza
pandem
investig
whether
advax
tm
novel
polysaccharid
adjuv
base
delta
inulin
microparticl
could
help
overcom
neonat
immun
hyporespons
first
test
whether
possibl
use
advax
obtain
singledos
vaccin
protect
neonat
pup
lethal
influenza
infect
inactiv
influenza
vaccin
combin
advax
tm
adjuv
administ
singl
subcutan
immun
mous
pup
significantli
enhanc
serum
influenzaspecif
igm
level
associ
fold
increas
frequenc
splenic
influenzaspecif
igm
igg
antibodi
secret
cell
pup
immun
advax
significantli
higher
splenocyt
influenzastimul
product
cba
fold
higher
frequenc
secret
cell
elispot
immun
advax
induc
robust
protect
pup
viru
challeng
week
later
wherea
pup
immun
antigen
alon
protect
protect
advaxadjuv
depend
memori
b
cell
rather
memori
cell
protect
neonat
mt
mice
bcell
defici
henc
advax
adjuv
overcam
neonat
immun
hyporespons
enabl
singledos
protect
pup
otherwis
lethal
influenza
infect
therebi
support
ongo
develop
advax
tm
neonat
vaccin
adjuv
young
children
elderli
next
highest
influenza
diseas
burden
pediatr
case
repres
annual
influenza
death
inde
influenzarel
hospit
rate
children
year
compar
hospit
rate
year
old
increas
diseas
burden
young
children
reflect
immun
system
immatur
lack
previou
influenza
exposur
poor
hygien
high
commun
contact
school
highlight
high
influenza
transmiss
risk
children
serolog
data
hong
kong
pandem
show
children
age
year
infect
earli
pandem
compar
age
year
advisori
committe
immun
practic
center
diseas
control
prevent
american
academi
pediatr
recommend
annual
influenza
vaccin
extend
children
month
age
mostli
immunolog
naiv
influenza
young
children
gener
requir
two
dose
month
apart
achiev
seroprotect
recent
cochran
review
estim
efficaci
trival
inactiv
influenza
viru
tiv
vaccin
prevent
influenza
children
two
year
old
neither
tiv
live
attenu
influenza
viru
laiv
vaccin
indic
children
month
due
poor
neonat
immun
respons
inactiv
vaccin
increas
respiratori
side
effect
laiv
vaccin
leav
infant
month
age
highli
http
elsevi
ltd
right
reserv
vulner
influenza
infect
make
imper
identifi
strategi
better
protect
popul
safeti
consider
must
alway
paramount
develop
vaccin
young
children
given
sensit
pyrogen
febril
convuls
reason
whole
viru
vaccin
rel
contraind
young
children
highli
purifi
split
subunit
antigen
prefer
reduc
vaccin
pyrogen
expens
reduc
immunogen
adjuv
could
use
enhanc
immunogen
influenza
vaccin
howev
limit
number
adjuv
test
young
children
guarante
adjuv
effect
adult
similarli
effect
neonat
highlight
potenti
difficulti
develop
safe
effect
influenza
vaccin
young
children
split
tiv
vaccin
fluvax
csl
australia
withdrawn
pediatr
use
caus
increas
febril
convuls
estim
three
excess
hospit
febril
convuls
everi
influenza
hospit
prevent
furthermor
pandemrix
monoval
inactiv
vaccin
adjuv
emuls
squalen
oil
polysorb
found
influenza
pandem
associ
increas
rate
narcolepsi
among
european
children
age
year
influenza
vaccin
recent
shown
two
immun
month
apart
induc
higher
antibodi
titer
unadjuv
vaccin
children
age
month
howev
influenza
vaccin
yet
shown
effect
safe
infant
month
age
make
imper
develop
effect
influenza
vaccin
young
infant
advax
tm
adjuv
novel
polysaccharid
adjuv
deriv
microparticl
polyfructofuranosyldglucos
delta
inulin
formul
inactiv
recombin
vaccin
antigen
prove
effect
enhanc
humor
cellular
immun
adult
anim
broad
rang
pathogen
includ
japanes
enceph
viru
west
nile
viru
anthrax
african
hors
sick
hiv
listeria
hepat
b
amongst
other
advax
enhanc
humor
cellular
immun
mice
inactiv
influenza
antigen
translat
improv
protect
influenza
challeng
vaccin
safe
even
administ
pregnant
mice
overcom
pregnancyassoci
immun
suppress
enhanc
vaccin
immunogen
pregnant
dam
secondari
benefit
enhanc
protect
pup
via
breast
milk
transfer
influenzaspecif
igg
advax
similarli
enhanc
vaccin
protect
adult
ferret
high
pathogen
avian
influenza
clinic
trial
pandem
influenza
vaccin
confirm
adult
enhanc
seroprotect
minim
side
effect
date
advax
adjuv
test
infant
given
problem
vaccin
hyporespons
young
children
current
studi
undertaken
test
abil
advax
adjuv
improv
influenza
vaccin
immunogen
protect
neonat
mice
particular
object
test
whether
advax
adjuv
could
use
achiev
singledos
influenza
protect
neonat
therebi
help
avoid
need
two
immun
current
recommend
influenza
protect
young
children
month
age
balbc
mt
background
mice
suppli
central
anim
facil
flinder
univers
south
australia
litter
neonat
mice
micegroup
immun
day
age
singl
subcutan
sc
inject
hind
thigh
l
g
bpl
inactiv
influenza
apuerto
advanc
biotechnolog
inc
columbia
md
usa
alon
togeth
mg
advax
delta
inulin
adjuv
vaxin
pti
ltd
adelaid
australia
control
group
inject
salin
alon
procedur
perform
accord
anim
experiment
guidelin
nation
health
medic
research
council
australia
approv
flinder
anim
welfar
committe
three
week
post
immun
blood
sampl
collect
cheek
vein
bleed
retroorbit
plexu
bleed
anesthesia
intraperiton
ip
inject
mgkg
ketamin
mgkg
medetomidin
immun
challeng
experi
repeat
least
time
confirm
reproduc
result
viru
use
challeng
experi
mouseadapt
influenza
apuerto
viru
propag
allanto
fluid
old
embryon
hen
egg
purifi
sucros
densiti
gradient
ultracentrifug
store
c
use
mous
lethal
dose
ld
estim
adult
balbc
mice
reedmuench
method
one
adult
ld
correspond
tcid
mdck
cell
unless
otherwis
indic
viru
challeng
dose
use
tcid
ld
dose
gave
lethal
unimmun
neonat
mice
challeng
studi
unimmun
control
group
routin
includ
ensur
challeng
dose
complet
lethal
case
lethal
alway
observ
control
unimmun
infant
mice
mice
infect
intranas
administr
l
viru
sick
score
system
base
coat
condit
postur
activ
use
assess
extent
clinic
diseas
mice
evalu
daili
score
individu
symptom
ruffl
fur
absent
slightli
present
present
hunch
back
absent
slightli
present
present
activ
normal
reduc
sever
reduc
evalu
final
score
addit
individu
symptom
score
eg
anim
show
slightli
ruffl
fur
slightli
hunch
back
reduc
activ
score
mice
euthan
becam
moribund
develop
clinic
score
although
possibl
blind
challeng
bodyweight
clinic
score
independ
audit
flinder
univers
anim
welfar
committe
influenza
viru
specif
antibodi
determin
elisa
previous
describ
briefli
inactiv
apuerto
antigen
charl
river
ct
usa
use
coat
elisa
plate
block
l
dilut
serum
sampl
ad
follow
biotinyl
antimous
igg
igm
abcam
hrpconjug
streptavidin
bd
bioscienc
ad
hr
wash
tmb
substrat
kpl
gaithersburg
md
usa
ad
min
reaction
stop
l
phosphor
acid
optic
densiti
measur
nm
od
nm
use
versamax
plate
reader
analyz
use
softmax
pro
softwar
averag
od
nm
valu
obtain
neg
control
well
subtract
spr
experi
perform
biacor
ge
healthcar
sensor
chip
c
use
run
buffer
hbsep
mm
hepe
nacl
mm
edta
vv
surfact
ph
antigen
coval
immobil
use
wizard
amin
coupl
method
chip
activ
edcnh
min
follow
inject
gml
mm
sodium
acet
ph
excess
activ
carboxyl
group
block
ethanolamin
min
reach
final
immobil
level
ru
pool
mous
antisera
vaccin
group
dilut
hbsep
buffer
inject
onto
surfac
refer
surfac
lmin
min
bound
antibodi
character
sequenti
inject
l
antimous
subclass
specif
antibodi
gml
order
antiigm
lmin
chip
regener
mm
glycin
ph
sd
sensorgram
correct
subtract
signal
refer
flow
channel
mice
kill
cervic
disloc
bone
spleen
asept
collect
bone
marrow
isol
femur
flush
fbspb
spleen
homogen
grind
plunger
ml
syring
cell
strainer
bd
bioscienc
treat
red
blood
cell
rbc
lysi
buffer
cell
stain
trypan
blue
live
cell
count
hemocytomet
splenocyt
cellswel
restimul
day
ubottom
plate
greiner
bioon
gml
antigen
supernat
harvest
cytokin
measur
mous
cytokin
cba
kit
bd
bioscienc
analyz
fcap
array
softwar
soft
flow
hungari
ltd
tcell
deplet
g
antimous
clone
bio
x
cell
west
lebanon
usa
inject
ip
day
viru
challeng
deplet
verifi
flow
cytometri
use
peripher
blood
cell
treat
rbc
lysi
buffer
rat
antimous
clone
apcantimous
clone
peantimous
clone
bd
bioscienc
confirm
reduct
cell
rat
igg
enrich
naiv
rat
serum
ammonium
sulfat
precipit
use
neg
control
ninetysixwel
multiscreen
filter
plate
millipor
usa
prewet
ethanol
wash
twice
pb
coat
plate
coat
c
overnight
gml
bcell
elispot
gml
antimous
bd
bioscienc
mab
biolegend
san
diego
tcell
elispot
plate
wash
pb
block
rpmi
fc
total
splenocyt
gml
ad
triplic
plate
incub
c
h
bcell
elispot
h
tcell
elispot
plate
wash
time
pbstween
gml
detect
antibodi
pb
fc
ad
incub
overnight
c
discard
detect
antibodi
plate
wash
time
pbstween
incub
dilut
hrpstreptavidin
bd
bioscienc
h
rt
wash
spot
visual
use
aec
substrat
bd
bioscienc
plate
wash
twice
water
dri
analyz
immunospot
elispot
system
cellular
technolog
shaker
height
oh
usa
splenocyt
harvest
naiv
mous
spleen
half
splenocyt
puls
np
peptid
sequenc
asnenmetm
h
c
remain
half
incub
without
peptid
wash
pb
cell
label
incub
min
rt
either
cfse
life
technolog
peptidepuls
cell
cfse
hi
cfse
unpuls
cell
cfse
low
cfselabel
cell
wash
twice
pb
fc
mixtur
cfse
hi
cfse
low
cell
inject
intraven
tail
vein
hr
anim
sacrif
splenocyt
collect
analyz
flow
cytometri
mannwhitney
kruskalw
test
perform
use
graphpad
prism
version
window
graphpad
softwar
san
diego
surviv
curv
creat
use
kaplanmei
method
statist
analys
surviv
curv
use
logrank
mantelcox
test
comparison
p
consid
repres
signific
differ
data
shown
mean
sem
figur
p
p
p
first
ask
whether
singl
immun
without
adjuv
could
protect
neonat
mice
although
intramuscular
immun
rout
often
use
adult
immun
studi
possibl
use
rout
administ
vaccin
small
pup
henc
subcutan
sc
rout
use
sevendayold
balbc
pup
immun
sc
hind
limb
g
without
advax
adjuv
reach
week
age
immun
pup
challeng
intranas
homolog
influenza
viru
immun
alon
provid
protect
pup
rapid
weight
loss
death
day
postchalleng
even
highest
g
dose
fig
contrast
complet
protect
seen
pup
immun
g
advax
adjuv
surviv
pup
continu
gain
weight
throughout
challeng
period
consist
lack
clinic
diseas
partial
protect
also
seen
pup
immun
g
advax
surviv
although
survivor
lost
bodi
weight
recov
immun
g
advax
protect
surviv
indic
neonat
mice
could
protect
singl
high
dose
provid
formul
advax
adjuv
better
understand
mechan
wherebi
advax
adjuv
provid
enhanc
singledos
vaccin
protect
neonat
pup
challeng
studi
repeat
use
g
advax
dose
provid
complet
singledos
protect
first
studi
immun
pup
bled
week
age
measur
serum
antiinfluenza
antibodi
challeng
week
age
homolog
viru
pup
immun
advax
significantli
increas
serum
influenzaspecif
igm
level
week
postimmun
wherea
pup
immun
alon
low
undetect
level
antibodi
isotyp
fig
compar
rel
amount
antibodi
isotyp
immun
pup
surfac
plasmon
reson
spr
perform
use
pool
prechalleng
sera
vaccin
group
reveal
pup
immun
advax
produc
predominantli
igm
lesser
extent
fig
contrast
result
previous
publish
studi
adult
mice
immun
advax
induc
well
suggest
pup
mark
isotyp
bia
influenza
immun
consist
data
report
elsewher
subset
immun
pup
group
sacrif
week
postimmun
frequenc
influenzaspecif
igm
igg
antibodi
secret
cell
asc
measur
elispot
consist
serum
antibodi
significantli
increas
fold
frequenc
influenzaspecif
igm
igg
asc
seen
spleen
pup
immun
advax
versu
immun
alon
fig
challeng
week
postimmun
pup
immun
advax
gain
weight
minim
clinic
diseas
high
level
surviv
surviv
p
contrast
pup
immun
alon
lost
weight
high
clinic
score
succumb
infect
fig
sera
taken
advax
survivor
two
week
postchalleng
show
larg
rise
influenzaspecif
prechalleng
level
loss
prechalleng
igm
compon
fig
consist
vaccineinduc
igmsecret
b
cell
undergon
isotyp
switch
igm
product
respons
influenza
viru
exposur
character
mechan
wherebi
advax
adjuv
enhanc
neonat
protect
memori
tcell
respons
assess
immun
pup
splenocyt
isol
pup
week
postimmun
stimul
antigen
cytokin
measur
cultur
supernat
pup
immun
advax
significantli
higher
fold
influenzastimul
recal
product
tnf
compar
pup
immun
alon
fig
thu
although
neonat
typic
impair
vaccin
respons
immun
advax
adjuv
abl
overcom
defect
enhanc
tcell
product
next
test
cytokin
elispot
whether
higher
cytokin
recal
respons
advaximmun
pup
reflect
increas
frequenc
influenzaspecif
memori
cell
consist
bulk
cytokin
product
data
pup
immun
advax
fold
higher
frequenc
secret
memori
cell
compar
pup
immun
alon
fig
thu
immun
pup
advax
adjuv
success
overcam
neonat
immun
immatur
band
tcell
level
result
increas
influenzaspecif
serum
antibodi
level
increas
frequenc
antiinfluenza
memori
b
cell
memori
cell
interestingli
although
advax
induc
memori
tcell
respons
belong
subset
indic
pattern
cytokin
product
antibodi
product
pup
sole
natur
igm
even
influenza
viru
challeng
ask
therefor
whether
influenza
protect
advax
immun
pup
depend
memori
bor
tcell
mt
mice
lack
matur
b
cell
abil
make
antibodi
henc
test
role
memori
b
cell
neonat
protect
immun
wildtyp
wt
mt
pup
advax
challeng
influenza
viru
week
postimmun
previous
observ
wt
pup
immun
alon
lost
weight
succumb
infect
wherea
immun
advax
surviv
gain
weight
throughout
challeng
period
fig
contrast
neonat
mt
pup
includ
immun
advax
lost
weight
die
indic
protect
pup
advax
requir
function
b
cell
confer
memori
cell
alon
consist
result
tcell
deplet
advax
immun
wt
pup
time
challeng
reduc
surviv
indic
cell
requir
protect
advaximmun
wt
pup
fig
next
ask
whether
inabl
cell
provid
protect
mt
pup
reflect
inabl
neonat
make
cytotox
lymphocyt
ctl
address
question
perform
vivo
ctl
assay
postchalleng
wt
pup
survivor
previous
immun
advax
neonat
advaximmun
survivor
exhibit
high
level
target
cell
kill
indic
abl
gener
antiinfluenza
ctl
respons
viral
exposur
data
shown
sevendayold
pup
n
immun
sc
g
alon
advax
adjuv
serum
collect
week
postimmun
antibodi
determin
elisa
pool
sera
advax
immunis
group
preand
postchalleng
captur
biacor
chip
spr
analysi
rel
quantiti
antibodi
isotyp
determin
sequenti
inject
sensor
surfac
depict
rel
percentag
antibodi
isotyp
b
pup
group
sacrif
prechalleng
determin
frequenc
asc
spleen
elispot
c
remain
immun
pup
challeng
viru
week
postimmun
bodi
weight
sick
score
surviv
rate
monitor
week
potenti
advers
effect
advax
adjuv
assess
immun
pup
includ
inspect
inject
site
reaction
monitor
feed
behavior
growth
pup
receiv
advax
evid
inject
site
lesion
show
normal
develop
weight
gain
compar
control
pup
fig
consist
absenc
advers
effect
advax
adjuv
previous
seen
immun
studi
adult
mice
includ
pregnant
dam
result
confirm
advax
adjuv
abl
success
overcom
neonat
hyporespons
inactiv
influenza
immun
therebi
enabl
robust
singledos
protect
pup
otherwis
lethal
influenza
infect
immun
pup
singl
dose
advax
adjuv
induc
high
serum
igm
level
increas
frequenc
splenic
influenzaspecif
asc
advax
adjuv
also
enhanc
cellular
immun
increas
frequenc
influenzaspecif
memori
cell
increas
recal
cytokin
product
effect
advax
adjuv
protect
neonat
stand
contrast
adjuv
shown
ineffect
induc
neonat
influenza
protect
exampl
alumadjuv
influenza
vaccin
provid
protect
neonat
mice
despit
use
similar
influenza
model
one
current
studi
explain
fact
alum
adjuv
reduc
abil
induc
igg
product
bcell
affin
matur
germin
center
format
neonat
squalen
oil
emuls
adjuv
current
adjuv
approv
human
season
influenza
vaccin
recent
report
immun
neonat
mice
day
age
influenza
vaccin
fail
provid
protect
enhanc
antibodi
titer
consist
complet
lack
effect
neonat
despit
enhanc
protect
older
infant
adult
mice
given
two
dose
vaccin
regimen
stand
mark
contrast
outcom
seen
current
studi
advax
adjuv
induc
high
serum
level
igm
mice
singl
vaccin
dose
protect
otherwis
highli
lethal
influenza
challeng
henc
advax
adjuv
appear
uniqu
abil
overcom
neonat
immun
hyporespons
induc
vaccin
protect
young
mice
neonat
mice
requir
higher
antigen
dose
adult
mice
complet
influenza
protect
neonat
mice
known
higher
suscept
lethal
influenza
adult
like
reflect
immatur
innat
adapt
immun
system
similarli
increas
neonat
suscept
influenza
also
seen
human
epidemiolog
data
high
neonat
suscept
influenza
make
search
fig
advax
adjuv
affect
neonat
growth
sevendayold
pup
n
immun
sc
salin
g
without
advax
adjuv
bodyweight
pup
record
week
later
ns
signific
differ
group
effect
neonat
vaccin
strategi
imper
influenza
antigen
requir
requir
complet
protect
neonat
current
studi
might
translat
dose
need
protect
human
neonat
predict
advanc
human
studi
must
note
vaccin
regimen
use
current
studi
protect
singl
dose
wherea
typic
even
older
human
infant
requir
least
dose
seroprotect
world
health
organ
consequ
recommend
infant
age
mouth
receiv
two
g
dose
split
influenza
vaccin
month
apart
henc
even
though
high
dose
antigen
need
current
studi
singl
dose
protect
neonat
consider
scope
reduc
neonat
vaccin
dose
use
typic
twodos
regimen
advaxadjuv
influenza
vaccin
exampl
adult
mice
found
protect
twodos
regimen
requir
littl
onehundredth
dose
requir
singledos
protect
futur
studi
confirm
whether
twodos
regimen
advaxadjuv
influenza
vaccin
significantli
reduc
antigen
dose
requir
neonat
protect
neonat
protect
advaxadjuv
influenza
vaccin
depend
function
b
cell
protect
seen
immun
neonat
mt
mice
defici
b
cell
unabl
make
immunoglobulin
neonat
protect
advaxadjuv
influenza
vaccin
depend
tcell
immun
protect
observ
even
cell
deplet
prior
challeng
fact
cell
unabl
mediat
protect
immun
neonat
absenc
antibodi
surpris
tcell
cytokin
phenotyp
gener
immun
pup
appear
similar
phenotyp
previous
seen
adult
mice
tcell
protect
could
demonstr
suggest
cell
immun
pup
might
defect
effector
function
eg
cytotox
lymphocyt
ctl
differenti
howev
vivo
ctl
assay
perform
postchalleng
surviv
advax
immun
wt
pup
high
level
kill
influenza
peptidelabel
target
cell
seen
data
shown
suggest
neonat
cell
inde
abl
differenti
ctl
lack
tcell
protect
neonat
mt
pup
could
instead
reflect
slower
differenti
neonat
cell
lytic
ctl
effector
delay
ctl
differenti
shown
reason
defect
neonat
protect
herp
simplex
viru
furthermor
contrast
adult
neonat
cell
shown
fail
prolifer
migrat
lung
respons
influenza
infect
consist
qualit
differ
neonat
adult
tcell
function
advax
adjuv
enhanc
protect
b
cell
immun
immun
pup
impair
antibodi
product
affin
matur
immun
neonat
correl
impair
expans
follicular
helper
fh
lymphocyt
shown
neonat
mice
immun
tetanu
toxoid
absorb
alum
adjuv
poor
neonat
germin
center
format
postimmun
correl
delay
matur
follicular
dendrit
cell
fdc
notabl
influenza
vaccin
fail
induc
germin
center
antibodi
respons
mice
associ
failur
induct
function
fh
cell
thu
adjuv
except
advax
incap
correct
neonat
immun
defect
bcell
function
central
import
fh
fdc
optim
neonat
vaccin
respons
suggest
advax
yet
determin
mechan
improv
activ
expans
neonat
fh
cell
andor
fdc
interestingli
although
advax
immun
induc
almost
exclus
igm
isotyp
pup
consist
respons
induc
memori
cell
belong
well
subset
interest
recal
respons
typic
domin
neonat
murin
human
newborn
report
impair
respons
latter
caus
low
dendrit
cell
product
therefor
surpris
advaxadjuv
vaccin
induc
robust
recal
respons
neonat
mechan
advax
overcam
normal
neonat
bia
known
may
potenti
advantag
excess
bia
caus
eosinophil
lung
immunopatholog
seen
either
sar
coronaviru
sar
respiratori
syncyti
viru
rsv
immun
recent
studi
show
formul
inactiv
recombin
sar
vaccin
advax
adjuv
enhanc
protect
sar
also
prevent
eosinophil
lung
immunopatholog
henc
abil
advax
adjuv
enhanc
neonat
respons
reduc
otherwis
overwhelm
bia
could
major
benefit
neonat
vaccin
particularli
might
risk
bia
otherwis
induc
eosinophil
lung
immunopatholog
key
consider
develop
vaccin
adjuv
potenti
use
neonat
safeti
toler
children
highli
prone
febril
convuls
least
one
season
inactiv
influenza
vaccin
withdrawn
due
excess
reactogen
pyrogen
young
children
although
studi
pup
receiv
exactli
advax
dose
mg
previous
use
adult
mous
studi
adjuvantrel
advers
effect
observ
futur
doserespons
studi
test
whether
lower
dose
advax
use
pup
howev
testament
advax
safeti
pup
weight
gram
abl
toler
full
adult
dose
administ
adult
mice
even
human
size
dose
mg
advax
induc
pyrexia
unpublish
data
mean
measur
temperatur
pup
indic
pyrexia
postimmun
neonat
would
typic
associ
loss
bodi
weight
similarli
advers
effect
pregnant
dam
pup
observ
advax
administ
pregnanc
advax
also
alreadi
shown
safe
well
toler
adult
human
trial
evid
potenti
induc
pyrexia
abil
advax
adjuv
enhanc
neonat
vaccin
protect
rais
mani
question
includ
natur
mechan
wherebi
advax
adjuv
abl
correct
neonat
band
tcell
immatur
notabl
inject
advax
adjuv
alon
without
antigen
provid
nonspecif
protect
influenza
contrast
nonspecif
viru
protect
due
nonspecif
innat
immun
activ
seen
cpg
oligonucleotid
tlr
agonist
togeth
fact
nt
induc
pyrexia
even
administ
high
dose
suggest
advax
work
tradit
tlrmediat
signal
pathway
howev
exact
mechan
action
remain
area
activ
investig
conclus
pilot
studi
mice
show
advax
adjuv
abl
overcom
neonat
immun
immatur
enhanc
influenzaspecif
antibodi
tcell
respons
singledos
vaccin
protect
otherwis
lethal
influenza
infect
use
advax
adjuv
associ
advers
effect
support
strong
safeti
data
seen
anim
model
adult
human
clinic
trial
ongo
need
influenza
vaccin
effect
children
month
challeng
see
whether
promis
murin
data
advax
adjuv
translat
similar
benefit
larger
anim
model
ultim
human
infant
find
also
rais
possibl
advax
adjuv
might
similarli
benefici
enhanc
immunogen
vaccin
direct
neonat
exampl
rsv
tb
malaria
vaccin
project
fund
feder
fund
nation
institut
allergi
infecti
diseas
nation
institut
health
contract
collabor
research
contact
content
sole
respons
author
necessarili
repres
offici
view
nation
institut
health
yho
cho
np
associ
vaxin
pti
ltd
adelaid
australia
hold
proprietari
interest
advax
tm
adjuv
anim
challeng
studi
result
overseen
audit
flinder
univers
anim
welfar
committe
